Pan and colleagues published the results of anti-CD22 CAR T-cells in 34 pediatric and adult patients with R/R B-ALL who failed previous CD19-targeting CAR T-cell therapies. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.